10-Q: Molina Healthcare Q3 Net Income Plunges 76% on High Costs

Molina Healthcare reported a significant decline in third-quarter net income and diluted EPS, primarily driven by a challenging medical cost trend environment across all segments.

Summary

• Net income for the third quarter of 2025 was $79 million ($1.51 diluted EPS), a 75.8% decrease from $326 million ($5.65 diluted EPS) in the third quarter of 2024.
• Net income for the nine months ended September 30, 2025, was $632 million ($11.79 diluted EPS), down 31.9% from $928 million ($15.97 diluted EPS) in the same period of 2024.
• Total revenue increased 11% to $11.477 billion in Q3 2025 and 13% to $34.051 billion for the nine months, driven by the ConnectiCare acquisition, rate increases, and growth in the existing footprint.
• Consolidated Medical Care Ratio (MCR) rose to 92.6% in Q3 2025 from 89.2% in Q3 2024, and to 90.8% for the nine months from 88.8% in the prior year, exceeding the long-term target range.
• Membership grew 0.5% year-over-year to 5.6 million members as of September 30, 2025, with significant growth in Marketplace (+73.9%) and Medicare (+7.7%), partially offset by a decline in Medicaid (-6.2%).
• The General and Administrative (G&A) expense ratio improved to 6.4% in Q3 2025 and 6.5% for the nine months, reflecting operating discipline and leverage from business growth.

Sentiment

Score: 3

Explanation: The company reported a substantial decline in net income and operating income, primarily due to a challenging medical cost trend environment leading to significantly higher Medical Care Ratios (MCRs) across all segments, which are above the long-term target range. While revenue grew and G&A expenses were managed, these positives were overshadowed by the medical cost pressures. Furthermore, new regulatory changes are expected to negatively impact future enrollment in key programs.

Positives

• Total revenue increased by 12% in Q3 2025 and 13% for the nine months ended September 30, 2025, driven by the ConnectiCare acquisition and rate increases.
• The General and Administrative (G&A) expense ratio improved to 6.4% in Q3 2025 (from 6.5% in Q3 2024) and to 6.5% for the nine months (from 6.9% in 2024), indicating operating efficiency and leverage.
• Overall membership increased by 0.5% year-over-year to 5.6 million, primarily due to strong growth in the Marketplace segment (+73.9%) and Medicare (+7.7%).
• Successfully secured new Medicaid contracts in Mississippi, Nevada, Florida, and Wisconsin, and a Medicare contract in Illinois, indicating continued strategic growth.
• Net unrealized gains on investments classified as current and available for sale increased to $12 million at September 30, 2025, compared to net unrealized losses of $75 million at December 31, 2024.

Negatives

• Net income for Q3 2025 plummeted by 75.8% to $79 million, and diluted EPS decreased by 73.2% to $1.51, compared to Q3 2024.
• Operating income decreased by 70.6% in Q3 2025 to $137 million and by 28.9% for the nine months to $943 million.
• The consolidated Medical Care Ratio (MCR) significantly increased to 92.6% in Q3 2025 (from 89.2% in Q3 2024) and to 90.8% for the nine months (from 88.8% in 2024), both exceeding the long-term target range.
• All segments experienced MCR increases, with Marketplace MCR rising sharply to 95.6% in Q3 2025 (from 73.0% in Q3 2024) due to higher utilization relative to risk adjustment revenue.
• Medicaid membership declined by 6.2% year-over-year due to redeterminations and the Virginia contract termination.
• Investment income decreased in both the three and nine-month periods due to a decline in prevailing interest rates.
• Incurred higher interest expense due to increased borrowings under credit facilities and senior notes.
• Prior year reserve development was less favorable in the nine months ended September 30, 2025 ($124 million favorable) compared to the same period in 2024 ($625 million favorable).

Risks

• Medicaid rate adjustments and updates in 2025 or 2026 may not be commensurate with current medical cost trends and member acuity levels.
• Federal or state legislative or regulatory changes, including the 'One Big Beautiful Bill Act' (OBBBA), could lead to reductions in Medicaid funding, changes to federal matching percentages, block grants, per capita caps, work requirements, or reduced provider taxes.
• The OBBBA is expected to reduce enrollment in state Medicaid programs (estimated 15-20% reduction in 1.3 million Expansion population) and national Marketplace enrollment.
• Budget pressures on state governments could lead to efforts to reduce rates or limit rate increases.
• Evolving Marketplace dynamics, including issues impacting enrollment, special enrollment periods, premium subsidies, risk adjustment estimates, and the potential for disproportionate enrollment of higher acuity members.
• Challenges in retaining existing or awarded government contracts and successful bid submissions in response to requests for proposal.
• Ability to integrate acquisitions and realize projected benefits.
• Subsequent adjustments to reported premium revenue based on new information, including retroactive Medicaid rate adjustments or changes to Marketplace risk adjustment estimates.
• Effective management of medical costs and ability to predict utilization rates with accuracy.
• Cyber-attacks, ransomware, or data security incidents leading to disclosure of protected information or operational delays.
• Operational improvements, efficiencies, and cost savings from AI administrative tools may be less than anticipated or result in unforeseen consequences.
• Impact of increasing pharmacy costs, including specialty drugs and formulary changes.
• Interpretation and implementation of medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions.
• Complications, member confusion, or enrollment backlogs related to the renewal of Medicaid coverage.
• Fraud, waste, and abuse matters, government audits, reviews, or investigations, and potential fines, sanctions, or premium recovery.
• Failure to comply with financial or other covenants in the Amended Credit Agreement or senior notes indentures.
• Availability of adequate financing on acceptable terms to fund expansion, growth, and liquidity needs.
• Risks associated with vaccine hesitancy and the potential for new epidemics or pandemics (e.g., H5N1 bird flu, measles).
• Impact of inflation on medical costs and the cost of refinancing outstanding indebtedness.

Future Outlook

The 'One Big Beautiful Bill Act' (OBBBA) is expected to reduce enrollment in state Medicaid programs by 15% to 20% of the 1.3 million Expansion population, with timing and magnitude varying by state. The OBBBA will also reduce national Marketplace enrollment due to limits on legal aliens eligible for premium tax credits and pre-enrollment eligibility verification. HHS's Marketplace Program Integrity and Affordability Rule is expected to further reduce Marketplace enrollment in 2026. The company expects the Medicaid and Medicare MCRs to remain above their long-term target ranges due to higher than expected medical costs from acuity shifts, product mix changes, and increased utilization. The impact of OBBBA's changes to provider taxes and payment limits (starting 2028) is uncertain, depending on state policy adaptations. The company is evaluating the impact of ASU 2025-06 on internal-use software accounting, effective for fiscal year ending December 31, 2028.

Management Comments

• The decline in net income in the third quarter of 2025 and nine months ended September 30, 2025 compared to the prior year reflects a decline in operating income for both periods. The decrease in operating income was mainly attributable to an increase in the MCR, higher interest cost and lower investment income, partially offset by the benefit of higher membership and G&A expense efficiencies.
• The consolidated MCR for the nine months ended September 30, 2025 is above our long-term target range.
• The increase in both periods [Medicaid MCR] was driven by higher than expected medical costs from acuity shifts, changes in product mix and an increase in utilization among our continuing population from the second half of 2024 that has continued into 2025.
• The Medicaid MCR for the third quarter and nine months ended 2025 is higher than we expected and is above our long-term target range.
• The Medicare MCR for the third quarter and nine months ended 2025 is above our long-term target range.
• The increase in MCR for both periods [Marketplace] was higher than expected, reflecting higher utilization relative to the risk adjustment revenue that we priced for among our continuing population and Special Enrollment Period members.
• We have a disciplined and steady approach to growth. Organic growth, which includes leveraging our existing health plan portfolio and winning new territories, is our highest priority.
• In addition to organic growth, we will consider targeted acquisitions that are a strategic fit that we believe will leverage operational synergies, and lead to incremental earnings accretion.
• Management believes that our regulated, wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements.

Industry Context

The healthcare industry is subject to significant government regulation and funding changes, as evidenced by the 'One Big Beautiful Bill Act' (OBBBA) and the HHS Marketplace Program Integrity and Affordability Rule. These legislative and regulatory changes are expected to impact enrollment and revenue across Medicaid and Marketplace programs nationally. The company is experiencing a 'very challenging medical cost trend environment,' particularly in the Marketplace segment, with higher utilization rates for behavioral health, high-cost drugs, and long-term services and supports (LTSS). This trend is likely affecting other managed care providers in government-sponsored programs. Consolidation in the Medicaid and general healthcare sector is noted as a risk, suggesting an environment of ongoing M&A activity. The company's strategy of pursuing organic growth through new contract wins and targeted acquisitions aligns with industry efforts to expand market share and achieve operational synergies in a competitive landscape.

Comparison to Industry Standards

• The consolidated MCR of 92.6% for Q3 2025 and 90.8% for the nine months ended September 30, 2025, is explicitly stated as 'above our long-term target range,' indicating underperformance relative to internal benchmarks.
• The significant increase in MCR, especially in the Marketplace segment (95.6% in Q3 2025 vs. 73.0% in Q3 2024), suggests that Molina Healthcare is facing greater medical cost pressures or less effective cost management compared to its own historical performance and potentially industry peers, though specific peer comparisons are not provided in the filing.
• The company's G&A ratio improvement (6.4% in Q3 2025 vs. 6.5% in Q3 2024) suggests effective cost control in administrative areas, which could be a positive differentiator if medical costs were better managed.
• The filing mentions 'increasing competition and consolidation in the Medicaid or general healthcare sector' as a risk, implying that the company operates in a dynamic environment where maintaining competitive MCRs and growth is crucial. No specific comparable companies or projects are mentioned for direct comparison within the filing.

Legal Proceedings

• The company is involved in legal actions in the ordinary course of business, including employment claims, vendor disputes, and provider claims.
• An adverse determination in these matters could have a material adverse effect on financial position, results of operations, or cash flows.
• The company accrues liabilities for probable and reasonably estimable losses related to legal matters.
• The company filed and then withdrew a legal action in Virginia Circuit Court over DMAS's decision not to award a CCMC 2.0 contract, leading to contract termination.

Stakeholder Impact

• Shareholders: Significant decrease in net income and EPS, coupled with rising MCRs, could negatively impact share price and investor confidence. Ongoing share repurchase programs might offer some support.
• Employees: The G&A ratio improvement mentions 'reduced incentive compensation tied to lower expected performance,' which could affect employee morale or compensation.
• Customers (Members): Regulatory changes like the OBBBA and HHS Marketplace rule are expected to reduce enrollment in Medicaid and Marketplace programs, potentially impacting access to services for some members.
• Government Agencies: The company's contracts with state and federal agencies are subject to competitive bidding, rate adjustments, and regulatory changes, impacting revenue and operational stability. The OBBBA specifically targets Medicaid funding and Marketplace subsidies.
• Providers: Changes in Medicaid payment limits (100% of Medicare rate for Expansion states, 110% for non-Expansion states) starting in 2028 could impact provider reimbursement.

Next Steps

• States are expected to implement changes from the 'One Big Beautiful Bill Act' (OBBBA) regarding Medicaid work requirements, redeterminations, and cost sharing from 2027 to 2029.
• The OBBBA's changes to provider taxes and payment limits are scheduled to begin in 2028, with full implementation expected over 5 to 15 years.
• HHS's Marketplace Program Integrity and Affordability Rule will shorten the open enrollment period starting in 2027 and eliminate certain special enrollment periods.
• The Nevada Medicaid and Children's Health Insurance Program managed care contracts are expected to begin on January 1, 2026.
• The Illinois Fully Integrated Dual Eligible Special Needs Plan contract is expected to go live on January 1, 2026.
• The Wisconsin Family Care and Family Care Partnership program contract in Geographic Service Regions 2 and 7 is expected to commence on January 1, 2026.
• Finalization of purchase price adjustments for the ConnectiCare acquisition is expected to occur in the first quarter of 2026.
• The company is evaluating the impact of ASU 2025-06, effective for annual reporting beginning with the fiscal year ending December 31, 2028.
• Management will continue to determine the exact timing and amount of share repurchases under the $1 billion program authorized in April 2025, which extends through December 31, 2026.

Key Dates

Recommendation

The filing reveals a substantial deterioration in profitability, with net income plunging 75.8% in Q3 2025 and the Medical Care Ratio (MCR) rising significantly across all segments, exceeding the company's long-term target. This indicates a challenging medical cost environment that the company is struggling to manage effectively. Furthermore, new regulatory changes, such as the 'One Big Beautiful Bill Act' and the HHS Marketplace rule, are projected to lead to reduced enrollment in key government-sponsored programs, creating significant headwinds for future revenue and membership growth. While the company is pursuing strategic acquisitions and share repurchases, these actions are unlikely to fully offset the fundamental operational and regulatory challenges impacting core profitability. The outlook for sustained earnings recovery appears weak given the persistent medical cost trends and impending policy changes.

Keywords

Molina Healthcare, MOH, healthcare, managed care, Medicaid, Medicare, Marketplace, health insurance, medical costs, MCR, premium revenue, net income, diluted EPS, ConnectiCare, acquisition, regulatory changes, OBBBA, risk adjustment, share repurchase, debt, financial results